Novel |
CA7 |
carbonic anhydrase 7 |
- Reversible hydration of carbon dioxide
|
- Ethoxzolamide
- Benzthiazide
- Cyclothiazide
- Methazolamide
- Hydroflumethiazide
- Acetazolamide
- Zonisamide
- Diclofenamide
- Ellagic acid
|
|
Novel |
CDH1 |
cadherin 1 |
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Integrin cell surface interactions
- Apoptotic cleavage of cell adhesion proteins
- Adherens junctions interactions
- RHO GTPases activate IQGAPs
- InlA-mediated entry of Listeria monocytogenes into host cells
|
|
- Gastric cancer
- Penile cancer
- Nasopharyngeal cancer
- Breast cancer
- Hepatocellular carcinoma
- Thyroid cancer
|
Novel |
CDH16 |
cadherin 16 |
|
|
|
Novel |
CDH3 |
cadherin 3 |
- Adherens junctions interactions
|
|
- Hypotrichosis, congenital, with juvenile macular dystrophy
- Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
|
Novel |
NQO1 |
NAD(P)H quinone dehydrogenase 1 |
- Regulation of ornithine decarboxylase (ODC)
|
- Menadione
- Dicoumarol
- Duroquinone
- 3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol
- ES-936
- Cibacron Blue
- Flavin adenine dinucleotide
- 5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione
- RH-1
- Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone]
- 3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE
- Cannabidiol
|
|
Novel |
PYGB |
glycogen phosphorylase B |
- Neutrophil degranulation
- Glycogen breakdown (glycogenolysis)
|
- Pyridoxal phosphate
- Alvocidib
|
|
Novel |
RND3 |
Rho family GTPase 3 |
|
- Guanosine-5'-Triphosphate
|
|
|
CSK |
C-terminal Src kinase |
- GAB1 signalosome
- Phosphorylation of CD3 and TCR zeta chains
- Integrin signaling
- PD-1 signaling
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Negative regulation of FLT3
|
- Dasatinib
- Staurosporine
- TG-100801
- Fostamatinib
|
|
|
CTNNA1 |
catenin alpha 1 |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Myogenesis
- Myogenesis
- RHO GTPases activate IQGAPs
|
|
|
|
CTNNB1 |
catenin beta 1 |
- Degradation of beta-catenin by the destruction complex
- Beta-catenin phosphorylation cascade
- TCF dependent signaling in response to WNT
- Formation of the beta-catenin:TCF transactivating complex
- Formation of the beta-catenin:TCF transactivating complex
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Apoptotic cleavage of cell adhesion proteins
- Deactivation of the beta-catenin transactivating complex
- Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
- Ca2+ pathway
- Adherens junctions interactions
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- Disassembly of the destruction complex and recruitment of AXIN to the membrane
- VEGFR2 mediated vascular permeability
- Myogenesis
- Myogenesis
- Signaling by GSK3beta mutants
- S33 mutants of beta-catenin aren't phosphorylated
- S37 mutants of beta-catenin aren't phosphorylated
- S45 mutants of beta-catenin aren't phosphorylated
- T41 mutants of beta-catenin aren't phosphorylated
- RHO GTPases activate IQGAPs
- Transcriptional Regulation by VENTX
- InlA-mediated entry of Listeria monocytogenes into host cells
- RUNX3 regulates WNT signaling
|
|
- Gastric cancer
- Colorectal cancer
- Endometrial Cancer
- Pilomatricoma; Epithelioma calcificans of Malherbe
- Thyroid cancer
- Hepatocellular carcinoma
|
|
CTNND1 |
catenin delta 1 |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- InlA-mediated entry of Listeria monocytogenes into host cells
|
|
|
|
DSP |
desmoplakin |
- Apoptotic cleavage of cell adhesion proteins
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
- Zinc
- Artenimol
- Zinc acetate
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
- Striate palmoplantar keratoderma
- Skin fragility-woolly hair syndrome
- Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
EPHA2 |
EPH receptor A2 |
- EPH-Ephrin signaling
- EPH-Ephrin signaling
- EPHA-mediated growth cone collapse
- EPHA-mediated growth cone collapse
- EPH-ephrin mediated repulsion of cells
- EPH-ephrin mediated repulsion of cells
|
- Dasatinib
- Phosphoaminophosphonic Acid-Adenylate Ester
- Regorafenib
- Fostamatinib
|
|
|
F2RL2 |
coagulation factor II thrombin receptor like 2 |
- Peptide ligand-binding receptors
- G alpha (q) signalling events
- Thrombin signalling through proteinase activated receptors (PARs)
- Thrombin signalling through proteinase activated receptors (PARs)
|
|
|
|
FGA |
fibrinogen alpha chain |
- Platelet degranulation
- Common Pathway of Fibrin Clot Formation
- Integrin cell surface interactions
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- MAP2K and MAPK activation
- Regulation of TLR by endogenous ligand
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Post-translational protein phosphorylation
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Amyloid fiber formation
|
- Alteplase
- Reteplase
- Anistreplase
- Tenecteplase
- Sucralfate
- Zinc
- Alfimeprase
- Ancrod
- EP-2104R
- Lanoteplase
- Thrombin
- Prothrombin
- Human thrombin
- Thrombin alfa
- Anti-inhibitor coagulant complex
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Afibrinogenemia; Dysfibrinogenemia
- Inherited thrombophilia
- Familial amyloidosis
|
|
JUP |
junction plakoglobin |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
|
|
KDR |
kinase insert domain receptor |
- Neurophilin interactions with VEGF and VEGFR
- VEGF binds to VEGFR leading to receptor dimerization
- Integrin cell surface interactions
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
|
- Sorafenib
- Sunitinib
- 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
- Cediranib
- Vatalanib
- XL999
- TG-100801
- XL820
- CYC116
- Ramucirumab
- Pegdinetanib
- RAF-265
- ABT-869
- IMC-1C11
- Semaxanib
- Pazopanib
- Midostaurin
- Axitinib
- 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide
- N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide
- N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide
- 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide
- N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE
- N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE
- 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one
- 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one
- N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide
- N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine
- Cabozantinib
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Fostamatinib
- Erdafitinib
- Foretinib
- Ripretinib
- Pralsetinib
|
|
|
P2RX4 |
purinergic receptor P2X 4 |
- Elevation of cytosolic Ca2+ levels
- Platelet homeostasis
- Purinergic signaling in leishmaniasis infection
|
- Promethazine
- Eslicarbazepine acetate
- Eslicarbazepine
|
|
|
P2RX6 |
purinergic receptor P2X 6 |
- Elevation of cytosolic Ca2+ levels
- Platelet homeostasis
|
|
|